211 related articles for article (PubMed ID: 15777265)
1. Antiangiogenesis by chemotherapeutic agents.
Ribatti D; Vacca A; Merchionne F; Presta M
Mini Rev Med Chem; 2005 Mar; 5(3):313-7. PubMed ID: 15777265
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic chemotherapeutic agents.
Schirner M
Cancer Metastasis Rev; 2000; 19(1-2):67-73. PubMed ID: 11191065
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis. A boost for tumor starvation.
Marx J
Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
[No Abstract] [Full Text] [Related]
6. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic scheduling of lower dose cancer chemotherapy.
Gately S; Kerbel R
Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis: a possible treatment option for prostate cancer?
Longoria RL; Cox MC; Figg WD
Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapy with angiogenesis inhibitors.
Ghilardi C; Bani MR; Giavazzi R
Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
[No Abstract] [Full Text] [Related]
11. Therapeutic targeting of the tumor vasculature.
Tozer GM; Bicknell R
Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
[TBL] [Abstract][Full Text] [Related]
12. Metronomic therapy: chemotherapy revisited.
Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
[TBL] [Abstract][Full Text] [Related]
13. Vascular normalization: a real benefit?
Ribatti D
Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
[TBL] [Abstract][Full Text] [Related]
14. The possible role of chemotherapy in antiangiogenic drug resistance.
Bocci G; Loupakis F
Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.
Ng SS; Figg WD
Cancer Biol Ther; 2004 Dec; 3(12):1212-3. PubMed ID: 15662130
[TBL] [Abstract][Full Text] [Related]
17. Tumor Angiogenesis: A Key Target for Cancer Therapy.
Marmé D
Oncol Res Treat; 2018; 41(4):164. PubMed ID: 29587285
[No Abstract] [Full Text] [Related]
18. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
19. Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer.
Rajabi M; Adeyeye M; Mousa SA
Curr Med Chem; 2019; 26(30):5664-5683. PubMed ID: 31250748
[TBL] [Abstract][Full Text] [Related]
20. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
